Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4

BACKGROUND: The efficacy and safety of nebulized glycopyrrolate inhalation solution (GLY), administered twice daily (BID) via the innovative eFlow(®) Closed System nebulizer (PARI Pharma GmbH, Starnberg, Germany), were demonstrated in two replicate, placebo-controlled, 12-week Phase III studies (GOL...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohar, Jill, Tosiello, Robert, Goodin, Thomas, Sanjar, Shahin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305132/
https://www.ncbi.nlm.nih.gov/pubmed/30587959
http://dx.doi.org/10.2147/COPD.S184808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305132/
https://www.ncbi.nlm.nih.gov/pubmed/30587959
http://dx.doi.org/10.2147/COPD.S184808

Ejemplares similares